Identifying biomarkers for cancers linked to BRCA1 mutations
Biomarkers For BRCA1-Deficient Cancers
This study is looking at how changes in the BRCA1 gene affect breast and ovarian cancer cells and how this might help us create new treatments that specifically target those cancer cells, which could be especially helpful for patients with BRCA1 mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11094694 on NIH RePORTER |
What this research studies
This research investigates the role of BRCA1 mutations in breast and ovarian cancers, focusing on how these mutations affect the Unfolded Protein Response (UPR) in cancer cells. By understanding the relationship between BRCA1 and UPR stress sensors, the study aims to develop new treatment strategies that specifically target BRCA1-deficient cancer cells. Patients with these mutations may benefit from therapies designed to exploit the vulnerabilities created by their cancer's unique biology. The research employs both in vitro and in vivo methodologies to explore these connections and potential treatment avenues.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast or ovarian cancer who have BRCA1 mutations.
Not a fit: Patients without BRCA1 mutations or those with other types of breast or ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with BRCA1-deficient cancers.
How similar studies have performed: Previous research has shown promising results in targeting UPR pathways in cancer, indicating potential for success in this novel approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Kong, Kimi Y — University of Texas Hlth Science Center
- Study coordinator: Kong, Kimi Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.